	US 12,270,032 B2
	Codon-optimized nucleotide sequences encoding an AP-1 transcription factor
Spencer Park, Seattle, WA (US); Queenie Vong, South San Francisco, CA (US); Blythe Sather, South San Francisco, CA (US); Byoung Ryu, South San Francisco, CA (US); and Marc Lajoie, South San Francisco, CA (US)
Assigned to LYELL IMMUNOPHARMA, INC., South San Francisco, CA (US)
Filed by Lyell Immunopharma, Inc., South San Francisco, CA (US)
Filed on Feb. 24, 2022, as Appl. No. 17/679,977.
Claims priority of provisional application 63/309,380, filed on Feb. 11, 2022.
Claims priority of provisional application 63/263,231, filed on Oct. 28, 2021.
Claims priority of provisional application 63/153,879, filed on Feb. 25, 2021.
Prior Publication US 2022/0307039 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/67 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/078 (2010.01); C12N 15/861 (2006.01)

CPC C12N 15/67 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 5/0634 (2013.01); C12N 15/8613 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

20 Claims

1. A polynucleotide comprising

a nucleotide sequence having at least 89% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 1;

wherein the nucleotide sequence encodes a c-Jun protein, and wherein the c-Jun protein comprises the amino acid sequence set forth in SEQ ID NO: 13.